Acesso livre
Acesso livre

Arquivos do dia: Dezembro 1, 2021

Orientações da OMS para o tráfego internacional em relação à variante Ômicron do SARS-CoV-2 (B.1.1.529).

1 Dez, 2021 | 15:43h

WHO advice for international traffic in relation to the SARS-CoV-2 Omicron variant (B.1.1.529) – World Health Organization

Comentário: Over-60s, vulnerable should postpone travel due to Omicron: WHO – MedicalXpress

Ver também os artigos mais recentes sobre o assunto:

Will omicron – the new coronavirus variant of concern – be more contagious than delta? A virus evolution expert explains what researchers know and what they don’t – The Conversation

WHO pleads for ‘rational’ Omicron response – MedicalXpress

Omicron: WHO warns of ‘high infection risk’ around globe – BBC

Video: Why Omicron is the most worrying Covid variant yet – video explainer – The Guardian

Doctors hope Omicron causes milder cases of Covid — but it’s still too early to say – STAT

Doctor: Many South Africans ill in surge have mild symptoms – Associated Press

New Findings Show the Omicron Variant Spread Widely At a Faster Pace Than Initially Thought – TIME

Why some researchers think the omicron variant could be the most infectious one yet – NPR

Omicron Covid variant ‘present in Europe at least 10 days ago’ – The Guardian

Netherlands says Omicron variant was already in country earlier than previously thought – CNN

Netherlands detections hint at earlier Omicron spread – CIDRAP

Epidemiologist awaits clearer picture on omicron – Harvard University

Pfizer research head envisions a sprint to develop Omicron vaccine, if it’s needed – STAT

Omicron COVID variant was in Europe before South African scientists detected and flagged it to the world – CBS News

Moderna boss predicts current vaccines may be less effective against Omicron – The Guardian

Wealthy nations starved the developing world of vaccines. Omicron shows the cost of this greed – The Conversation

Travel restrictions by country following the Omicron variant outbreak – CNN

Com dados de dispositivos móveis (wearable data), um sistema de alerta em tempo real pode ser útil na detecção precoce de Covid-19 e outros eventos estressores.

1 Dez, 2021 | 15:41h

Real-time alerting system for COVID-19 and other stress events using wearable data – Nature Medicine

Comentário: Scientists develop a smartwatch-based device for early detection of COVID-19 – News Medical

 

Comentário no Twitter

 

Painel do FDA recomenda (por pouco) a autorização da primeira pílula antiviral para tratar COVID-19.

1 Dez, 2021 | 15:39h

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID – STAT

Ver também: An FDA panel supports Merck COVID drug in mixed vote – NPR

Conteúdos relacionados:

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Mortalidade total de pacientes de COVID na Alemanha que receberam ECMO durante as primeiras 3 ondas da pandemia.

1 Dez, 2021 | 15:37h

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic – Critical Care

Outro estudo randomizado mostrou que o plasma convalescente não beneficia pacientes internados com Covid-19.

1 Dez, 2021 | 15:36h

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Conteúdos relacionados:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Comentário no Twitter

 

O fim da pandemia de COVID-19 está atrelado à confiança: a ciência sozinha não vai nos tirar disso.

1 Dez, 2021 | 15:34h

Ending the COVID-19 Pandemic Hinges on Trust – Think Global Health

 

Comentário no Twitter

 

Diretrizes desenvolvidas sob pressão. O caso das diretrizes “rápidas” e de baixa qualidade para COVID-19 e soluções potenciais.

1 Dez, 2021 | 15:33h

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions – Journal of Clinical Epidemiology

Estudo de coorte | Condições alérgicas parecem estar relacionadas a menor risco de infecção por COVID-19.

1 Dez, 2021 | 15:32h

Comunicado de imprensa: Allergic conditions linked to lower COVID-19 infection risk – BMJ

Estudo original: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax

Diretriz NICE | Tabaco: prevenção do consumo, promoção da interrupção do tabagismo e tratamento da dependência.

1 Dez, 2021 | 15:31h

Tobacco: preventing uptake, promoting quitting and treating dependence – National Institute for Health and Care Excellence

Relatório Clínico AAP | Promoção da participação de crianças e adolescentes com necessidades especiais em esportes, atividades físicas e de recreação.

1 Dez, 2021 | 15:29h

Promoting the Participation of Children and Adolescents With Disabilities in Sports, Recreation, and Physical Activity – Pediatrics

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.